Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Clinical Pharmacology"
DOI: 10.1002/bcp.70031
Abstract: Brigimadlin (BI 907828) is a potent, oral MDM2‐p53 antagonist under clinical investigation for the treatment of advanced solid tumours. A brigimadlin exposure–tumour growth inhibition (E‐TGI) model was developed to support the recommended phase II dose… read more here.
Keywords: brigimadlin; tumour growth; growth inhibition; exposure tumour ... See more keywords
Determinants of the recommended phase 2 dose of molecular targeted agents
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30579
Abstract: The recommended phase 2 dose (RP2D) of anticancer agents is determined traditionally by dose‐limiting toxicities. Nontoxicity or biological endpoints such as pharmacokinetics, pharmacodynamics, and efficacy can also be used to identify RP2D, which may be… read more here.
Keywords: targeted agents; phase dose; determinants recommended; recommended phase ... See more keywords
PHARMACOKINETIC ANALYSIS AND CLINICAL RESULTS OF THE PHASE 1 DOSE ESCALATION AND EXPANSION CXD101 TRIAL IN RELAPSED, REFRACTORY LYMPHOMA
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2439_186
Abstract: and anemia (12%). The overall response rate (ORR) was 71% (12/17 pts) and median progression‐free survival (PFS) was not estimable across all cohorts; ORR in each subtype was 80% (4/5 pts) in DLBCL with 1… read more here.
Keywords: cll; clinical results; analysis clinical; results phase ... See more keywords
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0235-2
Abstract: BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m2 every 4… read more here.
Keywords: phase; dose escalation; her2 targeted; cancer ... See more keywords
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of biopharmaceutical statistics"
DOI: 10.1080/10543406.2024.2424845
Abstract: Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity outcome, assuming a monotone dose-response relationship. However, this… read more here.
Keywords: oncology; toxicity; dose finding; phase dose ... See more keywords
Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.014
Abstract: Abstract Background Pamiparib is an investigational PARP1/2 inhibitor that has demonstrated brain penetration and PARP–DNA complex trapping in preclinical studies. In the phase 1 dose-escalation/expansion study of pts with advanced solid tumors, pamiparib was generally… read more here.
Keywords: phase dose; escalation expansion; oncology; dose escalation ... See more keywords
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0591
Abstract: Purpose: NC-6300 is a novel nanoparticle formulation of epirubicin that has a pH-sensitive linker conjugated to epirubicin. It exhibits selective tumor accumulation owing to enhanced permeability and retention effect. We conducted a phase 1b trial… read more here.
Keywords: soft tissue; phase dose; solid tumors; trial ... See more keywords
Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct129
Abstract: Background: Methylation is reported to support cancer immune tolerance. We conducted a phase 1 dose-escalation trial [NCT02998567] of combination guadecitabine (G; DNA hypomethylating agent) and pembrolizumab (P) in patients (pts) with advanced cancers. We hypothesized… read more here.
Keywords: dose escalation; treatment; cancer; phase dose ... See more keywords
Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct138
Abstract: Introduction: PF-06801591 is a humanized IgG4 monoclonal antibody that binds to the programmed cell death (PD-1) receptor and blocks its interaction with PD-1/2 ligands (PD-L1/2). In a phase 1 dose expansion study (NCT02573259), 106 patients… read more here.
Keywords: dose expansion; cancer; phase dose; cell ... See more keywords
Abstract CT202: Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct202
Abstract: BACKGROUND: Combining anti-PD-1/L1 antibodies and agents that restore cancer cell susceptibility to apoptosis may enhance antitumor activity. We report results from a phase 1b dose-expansion cohort of xevinapant, a first-in-class, oral, small-molecule IAP (inhibitor of… read more here.
Keywords: cell; phase dose; pts advanced; cancer ... See more keywords
Abstract CT097: IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct097
Abstract: Background: IMM27M is a humanized Fc-engineered IgG1 CTLA-4 monoclonal antibody with enhanced ADCC. In pre-clinical models, IMM27M could enhance immune responses and promote Treg depletion. The pre-clinical results showed IMM27M induced a significantly stronger anti-tumor… read more here.
Keywords: escalation study; solid tumors; dose escalation; phase dose ... See more keywords